Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the company will make presentations at the following upcoming events.

Arteriosclerosis, Thrombosis and Vascular Biology | Peripheral Vascular Disease (ATVB|PVD) 2016 Scientific Sessions - Nashville, May 5-7, 2016

May 6, 11:00 a.m. CDT - Stacey Melquist, Ph.D., Arrowhead senior scientist, and coauthors, will deliver a poster presentation titled, " Lipoprotein(a) targeting with RNAi delivery platforms in transgenic mice and cynomolgus monkeys" (Presentation Number 428)

IBC's 18 th Annual TIDES: Oligonucleotide and Peptide Therapeutics - Long Beach, California, May 9-12, 2016

May 9, 1:30 p.m. PDT - David Rozema, Ph.D., Arrowhead vice president of chemistry will deliver an oral presentation titled, " Protease-sensitive endosomal escape for delivery of siRNA in vivo"

May 9, 1:30 p.m. PDT - Qingguo Tian, Ph.D., Arrowhead bioanalytical project manager will deliver an oral presentation titled, " Sensitive and specific quantification of oligonucleotides in biological matrices using hybridization based LC-fluorescence assays"

5th Asian Conference on Hepatitis and AIDS (ACHA) - Nanjing, China, May 28-29, 2016

May 29, 4:50 p.m. CST (China Standard Tim) - Bruce Given, M.D., Arrowhead chief operating officer will deliver an oral presentation titled, " RNAi therapeutics for chronic HBV - Animal models"

Copies of presentation materials can be accessed on the Events and Presentations page under the Investors section of the Arrowhead website after each presentation is delivered.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead's RNAi-based therapeutics leverage this natural pathway of gene silencing. The company's pipeline includes ARC-520 and ARC-521 for chronic hepatitis B virus infection, ARC-AAT for liver disease associated with alpha-1 antitrypsin deficiency, ARC-F12 for hereditary angioedema and thromboembolic disorders, ARC-LPA for cardiovascular disease, and ARC-HIF2 for renal cell carcinoma.

For more information please visit, or follow us on Twitter @ArrowheadPharma. To be added to the Company's email list and receive news directly, please visit

Safe Harbor Statement under the Private Securities Litigation Reform Act:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including our ability to finance our operations, the future success of our scientific studies, our ability to successfully develop drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, and the enforcement of our intellectual property rights. Our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.

DYNAMIC POLYCONJUGATES is a trademark of Arrowhead Pharmaceuticals, Inc.

Source: Arrowhead Pharmaceuticals, Inc.

View source version on

Copyright Business Wire 2010